Regencell Bioscience Holdings Limited Ordinary Shares (RGC) is a publicly traded Healthcare sector company. As of May 21, 2026, RGC trades at $27.85 with a market cap of $13.74B and a P/E ratio of 38.67. RGC moved +3.31% today. Year to date, RGC is +1.29%; over the trailing twelve months it is +131.52%. Its 52-week range spans $0.09 to $83.60. Rallies surfaces RGC's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
RGC financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. RGC recently traded at $27.85. Market cap is $13.74B. P/E ratio is 38.67. Revenue is $3.16B.
| Metric | Value |
|---|---|
| Price | $27.85 |
| Market Cap | $13.74B |
| P/E Ratio | 38.67 |
| EPS | $0.72 |
| Dividend Yield | 0.22% |
| 52-Week High | $83.60 |
| 52-Week Low | $0.09 |
| Volume | 319 |
| Avg Volume | 0 |
| Revenue (TTM) | $3.16B |
| Net Income | $112.30M |
| Gross Margin | 0.00% |
| Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2017 | $3.16B | $112.30M | $0.72 |
| 2016 | $3.20B | $170.50M | $1.09 |
| 2015 | $3.13B | $153.20M | $0.99 |
| 2014 | $2.99B | $105.20M | $0.68 |
RGC analyst coverage data. Average price target: $0.00.